InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Closes on Registered Direct Offering for $6M

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has closed on its previously announced registered direct offering. The offering, which was with a single healthcare-focused U.S. institutional investor, was comprised of 1,714,286 shares of the company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,571,429 shares of common stock. The units were priced at $3.50 per share and accompanying warrant. According to the announcement, the warrants have an exercise price of $3.50 per share and are initially exercisable beginning six months following the date of issuance; they also expire five years from the initial exercise date. Gross proceeds from the offering total an estimated $6 million, which the company anticipated using for R&D expenses as well as general corporate purposes.

To view the full press release, visit

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company driving groundbreaking studies into clinical programs that are seeking to address major unmet medical needs. The company’s focus is a novel program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). For more information about the company, visit

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.